Acute Myeloid Leukemia Registry
All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.
Acute Myeloid Leukemia
Overall Survival, From diagnosis to exits by any cause, 60 months
This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey.

Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.

All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.